Drug Trial Radar · NCT04736758
A Clinical Study on the Safety and Efficacy of GP681 Tablets in the Treatment of Uncomplicated Acute Influenza
Last checked: Nov 19, 2026Latest source record: Jul 26, 2022 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
216
Actual
Start
Jan 8, 2021
Primary completion
Dec 18, 2021
Study completion Dec 18, 2021
Sponsor
- Lead sponsor
- Jiangxi Qingfeng Pharmaceutical Co. Ltd.Industry
- Sponsor type
- Industry
- First posted
- Feb 3, 2021
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Analyse the time of flu symptom relief in adults with uncomplicated acute influenza,to evaluate the antiviral effects of high and low doses of GP681 tablets, and explore the optimal dose for phase III clinical trials.
Conditions
- Influenza
Interventions
GP681 tabletDrug
influenza subjects is randomized 1:1:1 into GP681 tablet 40mg group,GP681 tablet 20mg group and Placebo group,with 72 patients in each group.subjects is given with GP681 tablet or GP681 Simulant only once to treat influenza.
GP681 SimulantDrug
influenza subjects is randomized 1:1:1 into GP681 tablet 40mg group,GP681 tablet 20mg group and Placebo group,with 72 patients in each group.subjects is given with GP681 tablet or GP681 Simulant only once to treat influenza.
Primary outcomes
What the sponsor says the trial is designed to measure.
- time to alleviation of influenza symptomsTime frame: Day 15
Locations
1 site in 1 country. Site status is shown where the registry gives one.
The First Affiliated Hospital of Nanchang University
Nanchang, Jiangxi, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.